High Risk Hematologic Malignancy

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ExCellThera
ExCellTheraQC - Montréal
1 program
1
Transplant with an expanded ECT-001 cord bloodPhase 21 trial
Active Trials
NCT03913026Active Not RecruitingEst. Jun 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
ExCellTheraTransplant with an expanded ECT-001 cord blood

Clinical Trials (1)

NCT03913026ExCellTheraTransplant with an expanded ECT-001 cord blood

UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

Start: Apr 2019Est. completion: Jun 2027
Phase 2Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space